[Cardioprotective effect of energostim in toxic allergic myocarditis].
Energostim is a combined drug comprising a mixture of nicotinamide adenine dinucleotide (0.5 mg), cytochrome C (10 mg), and inosine (80 mg), representing antihypoxant and antioxidant of direct action in one ampule. After pretreatment and subsequent 3-day energostim therapy of animals with 3-day toxico-allergic myocarditis (3d-TAM), the ECG was free of any rhythm disorders and showed evidence of improved conduction, restoration of the normal form of T-wave and the position of ST segment, while the content of myofibrillar fraction of creatine phosphokinase and toxic products of disturbed metabolism (degree of endotoxemia) decreased to the upper normal level. Under the action of energostim, neither pressure nor the maximum rate of pressure buildup in the left ventricle are reduced (as they do upon 3d-TAM); neither systolic and diastolic functions are disturbed, nor their coordination (r = 0.79 between dP/dtmin and dP/dtmax, p < 0.01). The restoration of contractile activity and maximum rate of relaxation of myocardial microfibrils during 3d-TAM is accompanied by an increase in the content of adenyl nucleotides, in the ATP/ADP, ADP/AMP, NAD/NADH, and NADP/NADPH ratios, and in the cytosol phosphorylation potential. The energostim-induced improvement in the energy supply system are accompanied by restoration of the ability of sarcoplasmic reticulum to efflux Ca2+. Thus, it is demonstrated that the effect of energostim is related to its ability to actively participate in intracell metabolic processes in myocardium, abolish necrotic changes and endotoxicosis, and restore homeostasis in the systems responsible for the contraction--relaxation process (thus preventing from the development of dysfunction of the left ventricle and the heart failure).
Sukoan
G V
GV
Republic Research Center for Medical Biophysics and Novel Biomedical Technologies, Ministry of Public Health of the Republic of Georgia, Gudamakarskii per. 2, Tbilisi, 380092 Georgia.
Antelava
A V
AV
Kavadze
I K
IK
Chikobava
E A
EA
Iarovaia
E V
EV
Karsanov
N V
NV
D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D001427:Bacterial Toxins; D002118:Calcium / Q000378:metabolism; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D003285:Contractile Proteins / Q000187:drug effects; D045304:Cytochromes c / Q000627:therapeutic use*; D004338:Drug Combinations; D004562:Electrocardiography; D004734:Energy Metabolism / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006967:Hypersensitivity / Q000150:complications / Q000517:prevention & control*; D007288:Inosine / Q000627:therapeutic use*; D009205:Myocarditis / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*; D009206:Myocardium / Q000378:metabolism; D009243:NAD / Q000627:therapeutic use*; D011817:Rabbits
D000975:Antioxidants; D001427:Bacterial Toxins; D002316:Cardiotonic Agents; D003285:Contractile Proteins; D004338:Drug Combinations; D009243:NAD; D007288:Inosine; D045304:Cytochromes c; D002118:Calcium